Journal
CLINICAL ONCOLOGY
Volume 27, Issue 7, Pages 420-426Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.clon.2015.02.008
Keywords
alpha/beta ratio; breast cancer; clinical trials; hypofractionation; prostate cancer; radiotherapy
Categories
Funding
- Medical Research Council [MC_ST_U13080]
- Cancer Research UK Core Grant [C5255/A15935]
- Cancer Research UK [12933, 16945] Funding Source: researchfish
- Medical Research Council [1383502] Funding Source: researchfish
Ask authors/readers for more resources
Breast cancer and prostate cancer are the most common cancers diagnosed in women and men, respectively, in the UK, and radiotherapy is used extensively in the treatment of both. In vitro data suggest that tumours in the breast and prostate have unique properties that make a hypofractionated radiotherapy treatment schedule advantageous in terms of therapeutic index. Many clinical trials of hypofractionated radiotherapy treatment schedules have been completed to establish the extent to which hypofractionation can improve patient outcome. Here we present a concise description of hypofractionation, the mathematical description of converting between conventional and hypofractionated schedules, and the motivation for using hypofractionation in the treatment of breast and prostate cancer. Furthermore, we summarise the results of important recent hypofractionation trials and highlight the limitations of a hypofractionated treatment regimen. (C) 2015 The Royal College of Radiologists. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available